Inhibitory Effect of Luteolin Liposome Solution by Animal Model for Atopic Dermatitis in NC/Nga Mice

Moon-Jae Choi; Young-Moo Lee; Byung-Suk Jin; Bae-Hwan Kim

doi:10.5625/lar.2010.26.1.47

Journal List > Lab Anim Res > v.26(1) > 1053649

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Choi, Lee, Jin, and Kim: Inhibitory Effect of Luteolin Liposome Solution by Animal Model for Atopic Dermatitis in NC/Nga Mice

Original Article

Lab. Anim. Res. 2010;26(1):47-53.

Published online: 17 March 2010

DOI: https://doi.org/10.5625/lar.2010.26.1.47

Inhibitory Effect of Luteolin Liposome Solution by Animal Model for Atopic Dermatitis in NC/Nga Mice

Moon-Jae Choi^1,², Young-Moo Lee², Byung-Suk Jin³, Bae-Hwan Kim^4,^∗

¹Nabion Corporation, Seoul, Korea

²Department of Chemical Engineering, Hanyang University, Seoul, Korea

³Department of Applied Chemistry, Dongduk Women's University, Seoul, Korea

⁴Department of Public Health, Keimyung University, Daegu, Korea

^∗Corresponding author: Bae-Hwan Kim, Department of Public Health, Keimyung University, 2800 Dalgubeoldaero, Dalseo-Gu, Daegu, 704-701, Korea Tel: +82-53-580-5933 Fax: +82-53-580-5164 E-mail: kim9399@kmu.ac.kr

Received 21 January 2010 Revised 15 February 2010 Accepted 13 March 2010

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Atopic dermatitis is a common chronic inflammatory skin disease, associated with marked inflammatory cells (of mast cells and eosinophils) and severe itching, which leads to clinical problems in the pediatric population. This study was designed to investigate the inhibitory effects of luteolin liposome solution, that is entrapped the hydrophobic luteolin (one of the flavonoids) into ethosome to improve its stability, by using hapten-induced atopic dermatitis animal model (NC/Nga mice). The luteolin liposome treated mice showed anti-inflammatory effect as evidenced by the lowering of erythema and edema in clinical observation, reduction of inflammatory cell infiltration and epidermal thickness in histopathological examination, when compared with TNCB induced controls. Luteolin liposome solution also reduced the serum IgE level which played important roles in the atopic dermatitis model. These results suggest that luteolin liposome solution has some merit in this formulation showing inhibitory effects for the atopic dermatitis.

Keywords: Atopic dermatitis, animal model, TNCB, luteolin liposome

REFERENCES

Falus A.., Merétey K.1992. Histamine: an early messenger in inflammatory and immune reactions. Immunol. Today. 13(5):154–156.

Friedman P.S.2006. Contact sensitization and allergic contact dermatitis immunobiological mechanisms. Toxicol. Lett. 162:49–54.

Furue M.., Terao H.., Moroi Y.., Koga T.., Kubota Y.., Nakayama J.., Furukawa F.., Tanaka Y.., Katayama I.., Kinukawa N.., Nose Y.., Urabe K.2004. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J. Dermatol. 31(4):277–283.

Goutet M.., Pépin E.., Langonné I.., Huguet N.., Ban M.2005. Identification of contact and respiratory sensitizers using flow cytometry. Toxicol. Appl. Pharmacol. 205(3):259–270.

Hruza L.L.., Pentland A.P.1993. Mechanism of UV induced inflammation. J. Invest. Dermatol. 15(2):111–115.

Kaefer C.M.., Milner J.A.2008. The role of herbs and spices in cancer prevention. J. Nutri. Biochem. 19:347–361.

Lee S.H.., Baek S.J.., Kim H.A.., Heo Y.2006. 2,4-dinitrochlorobenzene-induced atopic dermatitis like immune alteration in mice. J. Toxicol. Pub. Health. 22(4):357–364.

Malaviya R.., Morrison A.R.., Pentland A.P.1996. Histamine in human epidermal cells is induced by ultraviolet light injury. J. Invest. Dermatol. 106(4):785–789.

Matsuda H.., Watanabe N.., Geba G.P.., Sperl J.., Tsudzuki M.., Hiroi J.., Matsumoto M.., Ushio H.., Saito S.., Askenase P.W.., Ra C.1997. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int. Immunol. 9(3):461–466.

Matsumoto M.., Ra C.., Kawamoto K.., Sato H.., Itakura A.., Sawada J.., Ushio H.., Suto H.., Mitsuishi K.., Hikasa Y.., Matsuda H.1999. IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis. J. Immunol. 162(2):1056–1063.

McGirt L.Y.., Beck L.A.2006. Innate immune defects in atopic dermatitis. J. of Allergy and Clin. Immunol. 118(1):202–208.

Menzies-Gow A.., Ying S.., Sabroe I.., Stubbs V.L.., Soler D.., Williams T.J.., Kay A.B.2002. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J. Immunol. 169(5):2712–2718.

Mueller D.L.., Jenkins M.K.., Schwartz R.H.1989. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7:445–480.

Plitnick L.M.., Loveless S.E.., Ladics G.S.., Holsapple M.P.., Selgrade M.J.., Sailstad D.M.., Smialowicz R.J.2002. Cytokine profiling for chemical sensitizers: application of the ribonuclease protection assay and effect of dose. Toxicol. Appl. Pharmacol. 179(3):145–154.

Renz H.., Brodie C.., Bradley K.., Leung D.Y.., Gelfand E.W.1994. Enhancement of IgE production by anti-CD40 antibody in atopic dermatitis. J. Allergy Clin. Immunol. 93(3):658–668.

Schuller E.., Oppel T.., Bornhövd E.., Wetzel S.., Wollenberg A. 2004. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J. Allergy and Clin. Immunol. 114(1):137–143.

Schultz-Larsen F.., Hanifin J.M.2002. Epidemiology of atopic dermatitis. Immunol. Allergy Clin. North Am. 22:1–24.

Shiohara T.., Hayakawa J.., Mizukawa Y.2004. Animal models for atopic dermatitis: are they relevant to human disease? J. Dermatol. Sci. 36(1):1–9.

Taniguchi Y.., Kohno K.., Inoue S.., Koya-Miyata S.., Okamoto I.., Arai N.., Iwaki K.., Ikeda M.., Kurimoto M.2003. Oral administration of royal jelly inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice.

Touitou E.., Dayan N.., Bergelson L.., Godin B.., Eliaz M.2000. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties J. Control. Release. 65:403–418.

Touitou E.., Meidan V.M.., Horwitz E.1998. Methods for quantitative determination of drug localized in the skin. J. Control. Release. 56:7–21.

Wisselink M.A.., Willemse T. 2009. The efficacy of cyclosporine A in cats with presumed atopic dermatitis: A double blind, randomised prednisolone-controlled study. The Vet. Journal. 180:55–59.

Yano S.., Umeda D.., Yamashita S.., Yamada K.., Tachibana H.2009. Dietary apigenin attenuates the development of atopic dermatitis-like skin lesions in NC/Nga mice. J. Nutri. Biochem. 20(11):876–881.

Ying S.., Robinson D.S.., Meng Q.., Barata L.T.., McEuen A.R.., Buckley M.G.., Walls A.F.., Askenase P.W.., Kay A.B.1999. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J. Immunol. 163(7):3976–3984.

Yun J.W.., Kim H.., Kang H.J.., Koh J.Y.., Kim B.H.2008. Models for Atopic Dermatitis in NC/Nga Mice. Lab. Animal Research. 24(1):59–66.

Figure 1.

Gross lesions of NC/Nga mouse skin. A: Normal control, B: TNCB induced control, C: Luteolin liposome solution, D: Luteolin.

Figure 2.

Histological observation of NC/Nga mouse skin by H&E staining (×100) (red bar=50 µm). A: Normal control, B: TNCB induced control, C: Luteolin liposome solution, D: Luteolin.

Figure 3.

Histological observation of NC/Nga mouse skin by Toluidine blue staining (×100) (red bar=50 µm). A: Normal control, B: TNCB induced control, C: Luteolin liposome solution, D: Luteolin. There are many mast cells (arrow) in TNCB control (B).

Table 1.

The frequency of scratching in NC/Nga mice

Weeks	NC	TNCB	T1	T2
0	0.8±0.8^a	6.0±2.6^b	5.2±2.6^b	5.2±2.2^b
2	0.6±0.5^a	4.4±2.1^b	2.6±1.5^ab	2.4±1.7^ab

Unit: times in 30 minutes

NC: Normal control, TNCB: TNCB induced control, T1: Luteolin liposome solution, T2: Luteolin

Values with different superscripts (a,b) in the same row are significantly different (P<0.05) by ANOVA and Duncan's multiple range test.

Table 2.

Changes inf transepidermal water loss (TEWL) of NC/Nga mice

Weeks	NC	TNCB	T1	T2
0	12.08±2.93^a	75.04±13.89^b	80.28±15.58^b	76.44±27.05^b
2	12.34±3.78^a	41.68±12.78^b	38.44±20.27^b	⁰38.90±22.51^ab

Unit: g/m²/h NC: Normal control, TNCB: TNCB induced control, T1: Luteolin liposome solution, T2: Luteolin Values with different superscripts (a,b) in the same row are significantly different (P<0.05) by ANOVA and Duncan's multiple range test

Table 3.

Changes in water capacity of NC/Nga mice by Corneometer

Weeks	NC	TNCB	T1	T2
0	37.74±25.79^b	16.86±2.93^a	14.01±7.27^a	16.74±5.04^a
2	30.85±4.32^b0	019.06±11.22^a	19.86±4.37^a	20.23±7.19^a

Unit: Arbitrary unit NC: Normal control, TNCB: TNCB induced control, T1: Luteolin liposome solution, T2: Luteolin Values with different superscripts (a,b) in the same row are significantly different (P<0.05) by ANOVA and Duncan's multiple range test.

Table 4.

Epidermal thickness of NC/Nga mice

Weeks	NC	TNCB	T1	T2
2	27.54±6.02^a	105.63±43.37^c	34.87±10.91^ab	52.74±17.76^b

Unit: µm NC: Normal control, TNCB: TNCB induced control, T1: Luteolin liposome solution, T2: Luteolin Epidermal thickness was determined by the average of three sites (short, medium, long-size each) in same fields of microscope. Values with different superscripts (a,b,c) in the same row are significantly different (P<0.05) by ANOVA and Duncan's multiple range test.

Table 5.

Number of mast cells and ratio of degranulation by Toluidine blue staining

			NC		TNCB		T1			T2
Total No of	mast cell		79.2±1	1.5^a	176.6±17.	8^c	134.0±26.1	^b	12	5.3±37.8^b
Mean No o	of degranulati	on	.59±8	.6^a	0.117±12.	9^b	101.6±22.9	^b	00	.94±28.4^b
Deganulati	on/total No.		74.5	5	66.1		75.8			75.2

NC: Normal control, TNCB: TNCB induced control, T1: Luteolin liposome solution, T2: Luteolin The number of mast cells was determined by the average of five different fields with an eyepiece of ×100 magnification. Values with different superscripts (a,b,c) in the same row are significantly different (P<0.05) by ANOVA and Duncan's multiple range test.

Table 6.

Plasma IgE levels of NC/Nga mice

Weeks	NC	TNCB	T1	T2
2	734.0±364.6^a	4,303.3±523.0^c	3101.1±780.5^b	2,503.2±1,041.5^b

Unit: ng/mL NC: Normal control, TNCB: TNCB induced control, T1: Luteolin liposome solution, T2: Luteolin Values with different superscripts (a,b,c) in the same row are significantly different (P<0.05) by ANOVA and Duncan's multiple range test.

TOOLS

Similar articles